# EDGAR Filing Document

**Accession Number:** 0000315545
**File Stem:** 0001493152-26-018160
**Filing Date:** 2026-4
**Character Count:** 15326
**Document Hash:** d87ff591ad4ac307747c5da1d488ed68
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-018160.hdr.sgml**: 20260421

**ACCESSION NUMBER**: 0001493152-26-018160

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260420

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260421

**DATE AS OF CHANGE**: 20260420

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PROVECTUS BIOPHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0000315545
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 900031917
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36457
- **FILM NUMBER:** 26876566

**BUSINESS ADDRESS:**
- **STREET 1:** 800 S. GAY STREET
- **STREET 2:** SUITE 1610
- **CITY:** KNOXVILLE
- **STATE:** TN
- **ZIP:** 37929
- **BUSINESS PHONE:** (866) 594-5999

**MAIL ADDRESS:**
- **STREET 1:** 800 S. GAY STREET
- **STREET 2:** SUITE 1610
- **CITY:** KNOXVILLE
- **STATE:** TN
- **ZIP:** 37929

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PROVECTUS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20020417

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZAMAGE DIGITAL IMAGING INC
- **DATE OF NAME CHANGE:** 20011126

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SPM GROUP INC
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **April 20, 2026**

**PROVECTUS BIOPHARMACEUTICALS, INC.**

(Exact name of registrant as specified in charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36457** | **90-0031917** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |

---

**800 S. Gay Street, Suite 1610, Knoxville, TN 37929**

(Address of Principal Executive Offices) (Zip Code)

**(866) 594-5999**

(Registrant's Telephone Number, Including Area Code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u> General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **None** | **N/A** | **N/A** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01. Other Events.**

On April 20, 2026, Provectus Biopharmaceuticals, Inc. (the "Company") issued a press release announcing that it will hold its 2026 Annual Meeting of Stockholders (the "Annual Meeting") at Perkins Place, its planned new headquarters in Knoxville, Tennessee. The Annual Meeting is scheduled to be held on June 18, 2026.

Attached hereto as Exhibit 99.1, and incorporated herein by reference, is a copy of the press release.

**Other Information**

The Company and its directors, executive officers, and advisors may be deemed to be participants in the solicitation of proxies in connection with the proposals to be considered at the Annual Meeting. Stockholders may obtain additional information regarding the interests of those participants by reading the "Stock Ownership," "Proposal 1 Election of Directors," and "Certain Relationships and Related Transactions" sections of the Company's preliminary proxy statement filed with the Securities and Exchange Commission ("SEC") on April 20, 2026, and, when they become available, the Company's definitive proxy statement and other definitive proxy materials, and the Company's Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 26, 2026, and Quarterly Reports on Form 10-Q, as filed with the SEC.

A notice of internet availability of proxy materials with instructions for accessing the definitive proxy statement will be mailed to stockholders as of the record date of April 20, 2026. Stockholders may obtain free copies of the preliminary proxy statement and the Company's other SEC filings electronically by accessing the SEC's home page at http://www.sec.gov. Copies can also be obtained, free of charge, upon written request to the Company, Attn: Secretary, 800 S. Gay Street, Suite 1610, Knoxville, Tennessee 37929, (866) 594-5999.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| Exhibit<br> Number | Description |
| 99.1 | [Press Release, dated April 20, 2026](ex99-1.htm) |
| 104 | Cover Page Interactive Date File (the cover page XBRL tags are embedded within the inline XBRL document) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 20, 2026

---

| | |
|:---|:---|
| **PROVECTUS BIOPHARMACEUTICALS, INC.** | **PROVECTUS BIOPHARMACEUTICALS, INC.** |
| By: | */s/ Heather Raines*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; |
|  | Heather Raines |
|  | Chief Financial Officer (Principal Financial Officer) |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

**Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee**

● Company Marks First Annual Meeting at Historic Perkins Place Office Building as It Prepares to Relocate Its Headquarters from First Horizon Plaza Tower

KNOXVILLE, Tenn., April 20, 2026 (GLOBE NEWSWIRE) — **Provectus Biopharmaceuticals, Inc.** ("Provectus" or the "Company") (OTCQB: PVCT) today announced that it will hold its 2026 Annual Meeting of Stockholders on Thursday, June 18, 2026, beginning at 4:00 p.m. Eastern Time, at the Perkins Place Office Building ("Perkins Place"), 525 Portland Street, Knoxville, Tennessee 37919.

Perkins Place is Provectus's planned new headquarters. The Company intends to relocate from its current offices at 800 S. Gay Street, Suite 1610 (First Horizon Plaza Tower) to Perkins Place in 2026. Holding this year's Annual Meeting at the new location marks the first stockholder gathering at what Provectus expects to become its permanent operational home.

**A Building with History and Strategic Alignment**

Designed by <u>Barber & McMurray Architects</u> and opened in 1927 as Perkins Elementary School, Perkins Place was named in honor of <u>Angie Villette Warren Perkins,</u> the first woman elected to the Knoxville Board of Education and the first woman in Tennessee to serve as president of a public-school board, when she was elected president of the Knoxville board in 1918. The building is a 22,941 square foot structure on a campus on 3.23 acres, fully renovated, with ample parking and sufficient land for future expansion.

Perkins Place carries a direct connection to Ed Pershing, Provectus's Chairman and Chief Executive Officer. He first encountered the building in 1991, when he envisioned it as the future home of Pershing Yoakley & Associates ("PYA"), the national healthcare consulting and accounting firm he co-founded in 1983. PYA acquired and restored the building in 1992, preserving its period architecture and converting it into a distinctive corporate headquarters and presence. PYA occupied Perkins Place until 2009, when PYA's growth demanded it double its office space. In the fall of 2025, Mr. Pershing reacquired the property through a partnership with the East Tennessee Foundation that independently sought the building for its own permanent home. The arrangement secured a headquarters for Provectus and provided the Foundation with a minority ownership interest and a long-term headquarters.

Provectus's planned relocation will provide the Company a pathway to effectively manage costs as it grows and adds resources. Additional land and flexible zoning create optionality for future facility development, including the potential for dedicated research, operational, and/or logistics-adjacent space.

Mr. Pershing said, "Holding our 2026 Annual Meeting of Stockholders at Perkins Place is the right setting for this moment. The building's history reflects values we recognize in ourselves: vision applied to overlooked assets, perseverance, and outcomes others considered improbable. Provectus's proprietary synthetic small molecule Rose Bengal Sodium is a molecule being systematically recognized and developed across oncology, dermatology, ophthalmology, and beyond. Perkins Place was not a new building when PYA first claimed it. In both cases, the value was already there. The work was to see it, commit to it, and build. We are planning to do that again at Provectus. Perkins Place is evidence of our expanding vision for Provectus".

**About Provectus**

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing a pipeline of immunotherapy medicines based on rose bengal sodium, a first-in-class synthetic small molecule from the halogenated xanthene family. The Company's clinical programs span oncology, dermatology, and ophthalmology, with additional proof-of-concept programs in hematology, wound healing, infectious diseases, and tissue repair.

For more information, visit <u>www.provectusbio.com</u>.

**Forward Looking Statements**

The information in this press release may include "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "aim," "likely," "outlook," "seek," "anticipate," "budget," "plan," "continue," "estimate," "expect," "forecast," "may," "will," "would," "project," "projection," "predict," "potential," "targeting," "intend," "can," "could," "might," "should," "believe," and similar words suggesting future outcomes or statements regarding an outlook.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.

Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.

Risks, uncertainties, and assumptions include those discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), including those described in Item 1A of the Company's Annual Report on <u>Form 10-K for the period ended December 31, 2025</u>.

**Additional Information and Where to Find It**

Stockholders are urged to read the definitive proxy statement when it becomes available, because it will contain important information about the Company and the 2026 Annual Meeting proposals.

This press release is not a proxy statement or solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the 2026 Annual Meeting proposals. STOCKHOLDERS ARE URGED TO READ CAREFULLY AND, IN ITS ENTIRETY, THE PRELIMINARY PROXY STATEMENT FILED WITH THE SEC AND, WHEN THEY BECOME AVAILABLE, THE DEFINITIVE PROXY STATEMENT AND OTHER RELEVANT MATERIALS, BECAUSE THEY DO AND WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE 2026 ANNUAL MEETING PROPOSALS. A notice of internet availability of proxy materials with instructions for accessing the definitive proxy statement will be mailed to stockholders as of the record date of April 20, 2026. Stockholders may obtain free copies of the Company's preliminary proxy statement and its other SEC filings electronically by accessing the SEC's home page at <u>http://www.sec.gov</u>. Copies can also be obtained, free of charge, upon written request to Provectus Biopharmaceuticals, Inc., Attn: Secretary, 800 S Gay St, Suite 1610, Knoxville, Tennessee 37929, (866) 594-5999.

**Participants in Solicitation**

This press release may constitute soliciting material under SEC Rule 14a-12, and the Company and its directors, executive officers, and advisors may be deemed to be participants in the solicitation of proxies from the holders of the Company's common stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock in respect of the 2026 Annual Meeting proposals.

Investors may obtain additional information regarding the interest of those participants by reading the "Stock Ownership," "Proposal 1 Election of Directors," and "Certain Relationships and Related Transactions" sections of the Company's preliminary proxy statement filed with the SEC on April 20, 2026 and, when they become available, the Company's definitive proxy statement and other relevant proxy materials, and the Company's annual report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 26, 2026, and quarterly reports on Form 10-Q, as filed with the SEC.

**Contacts:**

Provectus Biopharmaceuticals, Inc.

Heather Raines, CPA

Chief Financial Officer

<u>hraines@pvct.com</u>

(866) 594-5999

Investor Relations & Media

Susan Xu

<u>sxu@allianceadvisors.com</u>

(778) 323-0959